Resources

Selected
  • Pneumococcal disease
Type of publications
Regions
Diseases
Methodological quality (AMSTAR 2)
281 results found
2025 ∙ Vink, K. Kusters, J. Wallinga, J.
Chrono-optimizing vaccine administration: a systematic review and meta-analysis
Adults Older adults COVID-19 Influenza Hepatitis B Hepatitis A Pneumococcal disease Efficacy/effectiveness Administration
Rating:
Critically low
2025 ∙ Fletcher, M. A. Okasha, O. Baay, M. Syrochkina, M. Hayford, K.
Complicated pneumococcal pneumonia in the era of higher-valent pneumococcal conjugate vaccines: a systematic literature review and meta-analysis, 2001-2022
All age groups Pneumococcal disease Administration Efficacy/effectiveness
Rating:
Critically low
2025 ∙ Cao, B. K. Hanifa, R. S. Nguyen, T. P. Postma, M. J. van der Schans, J.
Economic evaluations of vaccines against respiratory infections in adults in Southeast Asia: A systematic review
South-East Asia Western Pacific Adults Older adults Influenza COVID-19 Pneumococcal disease Varicella Pertussis Economic aspects
Rating:
Not applicable
2025 ∙ Nimpa, M. M. Ntambue, A. Ngandu, C. Danovaro-Holliday, M. C. Bita Fouda, A. Cikomola, A. M. W. Mukendi, J. C. Mwamba, D. Aluma, A. D. L. Yapi, M. D. Nikiema, J. B. Hama Sambo, B. Ishoso, D. K.
Effects of Pneumococcal Vaccination in Children Under Five Years of Age in the Democratic Republic of Congo: A Systematic Review
Africa Newborn Children Pneumococcal disease Efficacy/effectiveness Administration
Rating:
Critically low
2025 ∙ Akther, A. Laurie, C. Elton-Marshall, T. Ly, V. Sulis, G.
Healthcare workers' current practices, knowledge/awareness, barriers, and attitudes/perceptions related to pneumococcal vaccination of older adults: A mixed-methods systematic review
All age groups Healthcare workers Pneumococcal disease Acceptance
Rating:
Not applicable
2025 ∙ Rahimi, H. K. Jasim, A. A. Rezahosseini, O. Harboe, Z. B.
Immunogenicity and adverse effects of pneumococcal vaccines co-administered with influenza or SARS-CoV-2 vaccines in adults: A systematic review and Meta-analysis
Adults Older adults Pneumococcal disease Influenza COVID-19 Efficacy/effectiveness Safety Administration
Rating:
Low
2025 ∙ Niyati, R. Rezahosseini, O. Ekenberg, C. Larsen, C. S. Harboe, Z. B.
Immunogenicity and Safety of Pneumococcal Vaccines Co-Administered with Common Travel Vaccines in Adults: A Systematic Review +
Adults Older adults Pneumococcal disease Efficacy/effectiveness Safety Administration
Rating:
Low
2025 ∙ Ngamprasertchai, T. Ruenroengbun, N. Kajeekul, R.
Immunogenicity and Safety of the Higher-Valent Pneumococcal Conjugate Vaccine vs the 13-Valent Pneumococcal Conjugate Vaccine in Older Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Adults Older adults Pneumococcal disease Efficacy/effectiveness Safety Administration
Rating:
Low
2025 ∙ Ul Haq, M. Z. Irfan, H. Shah, M. S. U. Sumbal, A. Mughal, S. Ashraf, S. Basaria, A. A. A. Abdullah, Chacho, M. A. Ayalew, B. D.
Immunogenicity, safety and tolerability of 15-valent pneumococcal conjugate vaccine (V114) compared to 13-valent pneumococcal conjugate vaccine (PCV-13) in healthy infants: A systematic review and meta-analysis
Newborn Pneumococcal disease Efficacy/effectiveness Safety Administration
Rating:
Low
2025 ∙ Amare, S. N. Yee, K. C. Leung, M. Naunton, M. Bushell, M.
Impact of pharmacist-led interventions on COVID-19, herpes zoster, influenza, pneumococcal, and respiratory syncytial virus vaccines uptake in people aged 60 years and older: Systematic review and meta-analysis
Adults Older adults Herpes zoster Influenza Pneumococcal disease RSV (Respiratory syncytial virus) COVID-19 Coverage
Rating:
Not applicable
Loading...